CRISPR based Universal CAR-T (UCAR-T) Platform

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite their remarkable clinical efficacy, autologous CAR-T therapies are hindered by high manufacturing costs, prolonged vein-to-vein times, and batch-to-batch variability, while allogeneic approaches face the persistent risks of graft-versus-host disease and rapid immune rejection. Our CRISPR-Based Universal CAR-T (UCAR-T) Platform combines multiplexed gene editing with streamlined, scalable vector engineering to generate off-the-shelf, healthy-donor-derived T cells. We offer a fully customizable service, from gRNA design and delivery to CAR construction and clonal selection, tailored to your specific target antigen and regulatory requirements. Our platform ensures high editing efficiency, minimal off-target effects, and robust in vivo persistence, thereby accelerating development timelines, reducing costs, and delivering consistent, high-quality UCAR-T products ready for preclinical and translational research.

Introduction

Allogeneic universal CAR-T (UCAR-T) therapies, derived from healthy donor T cells, represent a paradigm shift in adoptive cell therapy by enabling off-the-shelf availability, standardized manufacturing, and immediate treatment access, thereby circumventing the logistical and biological constraints inherent to patient-specific autologous products. The integration of CRISPR-enabled genome engineering into the UCAR-T development platform has further revolutionized this field, allowing for precise, multiplexed genetic modifications, such as simultaneous disruption of the T cell receptor alpha chain (TRAC), HLA class I molecules, and immune checkpoint genes, to mitigate graft-versus-host disease, reduce immune rejection, and enhance antitumor functionality, yielding a more potent, persistent, and broadly applicable therapeutic product with predictable performance across diverse patient populations.

Fig.1 Establishing universal CAR T cells employing genome editing. (OA Literature) Fig.1 Engineering universal CAR-T cells using genome editing.¹

Our Service

Our platform leverages precise multiplex gene editing to engineer off-the-shelf, allogeneic T cell therapies from healthy donor-derived PBMCs. By disrupting TCR and HLA expression, we eliminate GvHD and minimize host rejection, enabling scalable, cost-effective manufacturing. We provide end-to-end development from gene editing and CAR transduction to rigorous quality control, delivering high-purity, ready-to-infuse cell banks with safety and efficacy data to accelerate your translational programs.

What We Can Offer

Our platform offers a complete suite of CRISPR-based engineering strategies, from foundational immune-evasive edits to advanced functional modules, enabling the development of next-generation universal CAR-T cells with enhanced safety, persistence, and potent antitumor activity against relapse.

Featured services of CRISPR-based UCAR-T development platform at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors.
Vector carrying the CAR gene.

Key Steps:

Workflow of CRISPR-based UCAR-T development platform at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

A high-purity universal CAR-T (UCAR-T) cell bank that has undergone rigorous quality control and validation.
A complete report.

Key Advantages

Off-the-Shelf Availability: This platform enables mass production of standardized CAR-T cells from healthy donors, ensuring immediate "off-the-shelf" availability that eliminates the prolonged manufacturing wait times inherent to autologous products.
Mitigation of GvHD: By leveraging CRISPR/Cas9 to disrupt the T cell receptor (TCR) constant chain, the platform eliminates the risk of GvHD through precise ablation of alloreactivity.
Advanced Multi-Gene Engineering Capacity: The high-throughput, multiplex gene-editing capability allows for the simultaneous integration of dual or tandem CAR constructs, countering tumor antigen escape and reducing relapse rates.
Functional Enhancement and Persistence: Through targeted knockout of intrinsic negative regulators or site-specific CAR transgene integration into genomic "safe harbors", the platform intrinsically enhances T-cell fitness, reduces exhaustion, and prolongs in vivo persistence.

FAQ

Q1: How does the platform prevent GvHD?

A1: The platform uses CRISPR/Cas9 to disrupt the T cell receptor (TCR) alpha chain constant region (TRAC), which prevents the donor T cells from recognizing and attacking the patient's healthy tissues—the primary cause of GvHD.

Q2: What are the potential safety risks of using CRISPR in UCAR-T?

A2: Primary concerns include off-target editing and the potential for genotoxicity, such as chromosomal rearrangements at the cut sites. These risks are mitigated through rigorous target design, advanced nucleases to improve specificity, and screening protocols.

Why Choose Us?

Our CRISPR-based UCAR-T Platform delivers truly off-the-shelf, cost-effective cellular therapeutics. By leveraging multiplex genome editing, we eliminate GvHD and resist host rejection, ensuring enhanced persistence. Our advanced engineering also incorporates pharmacological control and combats tumor escape, offering a superior, scalable, and safer solution for next-generation cancer immunotherapy.

Customer Reviews

"Our team has utilized this CRISPR-based UCAR-T Platform for over eighteen months to generate allogeneic candidates. The multiplex gene-editing workflow is exceptionally streamlined, allowing us to simultaneously disrupt TCR and HLA molecules with minimal off-target effects. Using this service has accelerated our preclinical timelines, enabling rapid progression from concept to functional validation." Dr. A* K*.

"We employed this development platform to engineer UCAR-T cells targeting solid tumor antigens. The precision of the CRISPR system, combined with the proprietary delivery method, yielded editing efficiencies exceeding 90% across multiple donor batches. Using this service gave us consistent, reproducible results that were critical for our comparative efficacy studies in murine xenograft models." James H. M*.

How to contact us?

Are you poised to advance your next-generation cell therapy initiative?

Our scientific and commercial strategy experts are prepared to engage with you on every stage of your program, from early target substantiation through to clinical-scale production. We invite you to connect with us to examine how our CRISPR-powered UCAR-T architecture can bolster your development portfolio. All inquiries receive rapid, personalized responses, accompanied by custom-fit technical documentation aligned with your objectives.

Reference

Tang, Tiffany C Y et al. "Donor T cells for CAR T cell therapy." Biomarker research vol. 10,1 14. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s40364-022-00359-3.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.